SkyePharma News
Most Popular SkyePharma Story
Abbott to buy Kos for $3.7B
Looking for a quick leg up in the blockbuster world of cholesterol management, Abbott Laboratories has struck a deal to buy Kos Pharmaceuticals for $3.7 billion. The deal will pay stockholders $78 a share compared to Friday's close of $50.09, a 56 percent premium. Kos makes Niaspan and Advicor, which boosts "good" cholesterol, and is in late-stage development of Simcor. Simcor combines Niaspan and Zocor, which cuts bad cholesterol. Kos also has programs for asthma and inhaled insulin. …
... Read more...Latest Headlines
- November 2, 2007
- August 6, 2007
- November 5, 2006
- May 21, 2006
- May 7, 2006
- April 20, 2006
- April 18, 2006
- February 7, 2006
- February 5, 2006
- February 1, 2006
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
